Lv4
730 积分 2023-05-06 加入
Role of EGFR and FASN in breast cancer progression
1个月前
已完结
Genetic Code Expansion History and Modern Innovations
2个月前
已完结
Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
2个月前
已完结
Extrachromosomal DNA in Cancer
2个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
4个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
4个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
4个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
5个月前
已完结
Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors
11个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
1年前
已完结
皖公网安备34019202002308
